Abstract: Microfluidic devices for sterilizing fluids using pulsed electric fields are disclosed. In some embodiments, a device may include first and second electrode layers and a spacer layer positioned between the electrode layers. The spacer layer may define one or more fluid channels extending between the electrode layers. A power supply may be coupled to the electrode layers and configured to supply voltage pulses to the electrode layers to generate electric field pulses within the fluid channels. In some embodiments, the electrode layers may be textured such that the electric fields generated in the fluid channels are non-uniform.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: The present invention encompasses intermediates for preparing compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: A method for dynamic management of a first level of verbosity of a component defined in a data network, the data network having a control center, each component allowing the execution of tasks and including a security management configuration associating a status message, forming a log, with the execution of a task of the component, each log associated with a task indicating an event and having a local level, the control center allowing the collection of a set of logs to supervise the network, the method including: detecting a stimulus by a control center; determining a component associated with the stimulus detected by the control center; modifying the first level of verbosity of the component to a second level of verbosity during a first given period, the modification being launched by generating a supervision command by the control center, the second level of verbosity being defined according to the stimulus.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: A method for dynamic management of a first level of verbosity of a component defined in a data network, the data network having a control centre, each component allowing the execution of tasks and including a security management configuration associating a status message, forming a log, with the execution of a task of the component, each log associated with a task indicating an event and having a local level, the control centre allowing the collection of a set of logs to supervise the network, the method including: detecting a stimulus by a control centre; determining a component associated with the stimulus detected by the control centre; modifying the first level of verbosity of the component to a second level of verbosity during a first given period, the modification being launched by generating a supervision command by the control centre, the second level of verbosity being defined according to the stimulus.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: A method for centralizing events for a multilevel hierarchical computer management system, the system including a plurality of source equipments generating events and a plurality of event collectors per level, the method including selecting by an upper level collector a lower level collector according to operational parameters and/or a link quality of service of the lower level collector; receiving by the collector the events from the selected lower level collector; periodically verifying if the selected collector is available and if not repeating the selection step; and comparing by the upper level collector its events with those from the unselected lower level collectors and receiving from one of these unselected lower level collectors the events that are different.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Abstract: This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

Abstract: A method of monitoring an object of value to optimize energy consumption, the object of value being equipped with an event detection device including: a circuit configured to provide contactless communication with a remote entity; a sensor configured to detect an event related to the monitoring of an object of value; a unit configured to collect energy; the method including a first step of collecting energy by the detection device; a second step, started following the detection of an event by the detection device, in the course of which energy collected during the first step is restored such that: the detection device activates at least one contactless communication circuit of a remote entity or searches for one; the detection device transmits to the contactless communication circuit of the remote entity information related to the detected event.

Abstract: This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

Abstract: This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

Abstract: This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.